Raahil Kajani, MD
Sports Medicine · Northridge, CANPI 1780245985
Payments from drug & device makers
Across 45 payments — averaging $250.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$10K
- Boehringer Ingelheim$130
- Neurelis, Inc.$124
- Amgen$101
- AbbVie$100
- Novartis$89
- plus $725 from 16 others
What the payments were for
- Grants$10,00089%
- Food & beverage$1,26911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 1 | $10,000 |
| Boehringer Ingelheim | 5 | $130 |
| Neurelis, Inc. | 4 | $124 |
| Amgen | 4 | $101 |
| AbbVie | 1 | $100 |
| Novartis | 3 | $89 |
| GSK | 4 | $85 |
| AstraZeneca | 3 | $74 |
| Saxum Surgical, Inc. | 1 | $72 |
| Sanofi-aventis U.S. LLC | 2 | $66 |
| Novo Nordisk | 3 | $66 |
| Phathom Pharmaceuticals, Inc. | 2 | $61 |
| Lilly USA, LLC | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Vifor Pharma, Inc. | 1 | $34 |
| Bayer | 1 | $30 |
| Philips North America LLC | 1 | $27 |
| Pfizer | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$100
How this compares
$11,269 in reported general payments places this provider in the 70th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naproxen | 16 | $517 |
| Losartan Potassium | 33 | $439 |
| Atorvastatin Calcium | 54 | $377 |
| Potassium Chloride | 11 | $352 |
| Tamsulosin Hcl | 12 | $252 |
| Escitalopram Oxalate | 17 | $235 |
| Omeprazole | 12 | $230 |
| Metformin Hcl | 16 | $195 |
| Amlodipine Besylate | 21 | $193 |
| Lisinopril | 11 | $175 |
| Furosemide | 12 | $157 |
| Fluticasone Propionate | 16 | $156 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $146 |
| Tramadol Hcl | 20 | $130 |
| Allopurinol | 12 | $114 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Northridge
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Seth ShermanStanford$1.8M
- Michael FreehillStanford$1.7M
- Deryk JonesSan Carlos$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Marc SafranPalo Alto$1.2M
- Stephan YacoubianBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.